APOC3 and Thrombocytopenia: Moreover, no adverse events related to thrombocytopenia were found, unlike what has been reported for volanesorsen, an antisense oligonucleotide-targeting APOC3 mRNA that showed results associated with thrombocytopenia in 76% of treated patients [33].